Ibopamine in glaucoma diagnostics: a new pharmacological provocative test
Gregorio, Fabio ; Giraldi, Josè Pecori ; Pannarale, Luigi ; Saccucci, Silvia ; Virno, Michele
Springer
Published 1996
Springer
Published 1996
| ISSN: |
1573-2630
|
|---|---|
| Keywords: |
ibopamine ; dopamine analogue ; glaucoma ; provocative test ; IOP
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296654078541824 |
|---|---|
| autor | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele |
| autorsonst | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele |
| book_url | http://dx.doi.org/10.1007/BF00212962 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM194447464 |
| issn | 1573-2630 |
| journal_name | International ophthalmology |
| materialart | 1 |
| notes | Abstract Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects. |
| package_name | Springer |
| publikationsjahr_anzeige | 1996 |
| publikationsjahr_facette | 1996 |
| publikationsjahr_intervall | 8004:1995-1999 |
| publikationsjahr_sort | 1996 |
| publisher | Springer |
| reference | 20 (1996), S. 151-155 |
| schlagwort | ibopamine dopamine analogue glaucoma provocative test IOP |
| search_space | articles |
| shingle_author_1 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele |
| shingle_author_2 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele |
| shingle_author_3 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele |
| shingle_author_4 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele |
| shingle_catch_all_1 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele Ibopamine in glaucoma diagnostics: a new pharmacological provocative test ibopamine dopamine analogue glaucoma provocative test IOP ibopamine dopamine analogue glaucoma provocative test IOP Abstract Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects. 1573-2630 15732630 Springer |
| shingle_catch_all_2 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele Ibopamine in glaucoma diagnostics: a new pharmacological provocative test ibopamine dopamine analogue glaucoma provocative test IOP ibopamine dopamine analogue glaucoma provocative test IOP Abstract Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects. 1573-2630 15732630 Springer |
| shingle_catch_all_3 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele Ibopamine in glaucoma diagnostics: a new pharmacological provocative test ibopamine dopamine analogue glaucoma provocative test IOP ibopamine dopamine analogue glaucoma provocative test IOP Abstract Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects. 1573-2630 15732630 Springer |
| shingle_catch_all_4 | Gregorio, Fabio Giraldi, Josè Pecori Pannarale, Luigi Saccucci, Silvia Virno, Michele Ibopamine in glaucoma diagnostics: a new pharmacological provocative test ibopamine dopamine analogue glaucoma provocative test IOP ibopamine dopamine analogue glaucoma provocative test IOP Abstract Purpose: Ibopamine is used when performing provocative tests, thanks to its pharmacological property of increasing ocular pressure in eyes with outflow system impairment. This study summarizes the latest results that we have achieved with reference to its clinical-diagnostic use. Methods: 175 (250 eyes) POAG patients, 101 (190 eyes) glaucoma suspects with mild ocular hypertension, 39 (64 eyes) NTG patients and 163 (326 eyes) healthy volunteers underwent an ibopamine provocative test. Among the POAG and the glaucoma suspects, 49 (92 eyes) and 20 (38 eyes) patients were selected who, starting from the performing of ibopamine test, had at least one year of perimetric follow-up. These patients have been assessed for the perimetric defect progression in relation to the (negative or positive) response to ibopamine. Results: the ibopamine test was positive for 92% of the glaucomatous patients, 61% of the glaucoma suspects, 52% of the NTG patients and 0% of the healthy volunteers. It was observed that 28% of the ibopamine-positive glaucoma suspects showed a perimetric deterioration during an average 2.5-year follow-up. No perimetric deterioration was found on ibopamine-negative glaucoma suspects (Fisher's exact test: p = 0.038). Among glaucomatous patients, 46% of the test-positive individuals showed a progressive trend of the perimetric defect, as against about 8% of glaucomatous test-negative patients (Fisher's exact test: p = 0.003). Conclusions: We believe that the ibopamine provocative test can be usefully applied especially to epidemiological screening studies to identify patients who might develop ocular hypertension or glaucoma and in the follow-up of glaucoma suspects, to identify individuals who have a greater risk of developing perimetric defects. 1573-2630 15732630 Springer |
| shingle_title_1 | Ibopamine in glaucoma diagnostics: a new pharmacological provocative test |
| shingle_title_2 | Ibopamine in glaucoma diagnostics: a new pharmacological provocative test |
| shingle_title_3 | Ibopamine in glaucoma diagnostics: a new pharmacological provocative test |
| shingle_title_4 | Ibopamine in glaucoma diagnostics: a new pharmacological provocative test |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:55:31.938Z |
| titel | Ibopamine in glaucoma diagnostics: a new pharmacological provocative test |
| titel_suche | Ibopamine in glaucoma diagnostics: a new pharmacological provocative test |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM194447464 |